Welcome to our dedicated page for Salarius Pharmaceuticals news (Ticker: SLRX), a resource for investors and traders seeking the latest updates and insights on Salarius Pharmaceuticals stock.
The news feed for Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) captures the company’s transition as it integrates Decoy Therapeutics and pivots toward a peptide-conjugate antiviral and oncology platform. Press releases and regulatory announcements describe how Salarius, historically a clinical-stage biopharmaceutical company with oncology assets, completed a strategic merger with Decoy and is preparing to operate under the Decoy Therapeutics name and the Nasdaq ticker symbol DCOY.
Readers following SLRX news can expect updates on corporate transformation, including the planned and then confirmed changes to the corporate name and trading symbol, as well as details of the merger structure, preferred stock issuance and leadership changes documented in company communications and SEC filings. The news flow also highlights capital markets activity, such as underwritten public offerings of common stock and warrants, at-the-market issuances and efforts to regain and maintain compliance with Nasdaq listing standards, including reverse stock splits and panel monitoring.
Sector-specific coverage focuses on drug development and platform progress. Company announcements describe the IMP3ACT peptide-conjugate platform, pan‑coronavirus and broad-acting antiviral programs, and a peptide drug conjugate targeting GI cancers. News items also cover collaborations, notably with Texas Biomedical Research Institute for in vitro testing of peptide conjugate fusion inhibitors across influenza strains including H5N1 avian flu, and recognition from programs such as the Massachusetts Life Sciences Seed Fund, the Google AI startup program, the NVIDIA Inception program and BARDA’s BLUE KNIGHT initiative.
By monitoring this page, investors and observers can review historical and ongoing disclosures around SLRX’s oncology heritage, its integration with Decoy’s AI- and ML-enabled peptide-conjugate platform, financing transactions and interactions with the Nasdaq Capital Market, all drawn from company-issued news and related filings.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a $0.9 million payment from the Cancer Prevention and Research Institute of Texas, part of a $1.7 million grant for its lead drug candidate, seclidemstat. This funding supports two clinical trials targeting Ewing sarcoma and advanced solid tumors. With a total of $4.8 million in remaining funds, Salarius is positioned to advance its clinical programs. The company has secured additional funding of $3.6 million from prior financing efforts, allowing it to progress through critical development milestones in 2021.
Salarius Pharmaceuticals is set to participate in the Biotech Showcase Digital and BIO @ JPM from January 11-15, 2021. This virtual participation coincides with the 39th Annual Healthcare Conference 2021. Salarius aims to discuss its clinical programs for seclidemstat, a potential treatment for Ewing sarcoma and other cancers. Key milestones include establishing maximum tolerated doses and advancing into the dose-expansion phase of trials. Salarius has received FDA designations for its lead candidate, focusing on pediatric and solid tumors.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced agreements with institutional investors to exercise outstanding warrants, raising approximately $3.5 million by issuing 3,964,065 shares. This follows their public offering in February 2020. The exercised warrants' price was reduced from $1.15 to $0.90 to encourage immediate cash exercise. New warrants will allow the purchase of additional shares at $1.182, exercisable in six months. The funds will support the development of seclidemstat, focusing on pediatric and solid tumors, with key milestones expected in early 2021.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced a $0.8 million payment under its contract with the Cancer Prevention and Research Institute of Texas (CPRIT), part of a total expected of $1.7 million. This funding supports the development of seclidemstat, its lead drug candidate, being evaluated in clinical trials for Ewing sarcoma and advanced solid tumors. Salarius aims to achieve several milestones, including determining the maximum tolerated dose in the Ewing sarcoma trial and expanding the study to include related sarcomas. Total CPRIT disbursements will reach $11.3 million with this funding.
Salarius Pharmaceuticals (Nasdaq: SLRX) announced CEO David Arthur's participation in A.G.P.’s Virtual Healthcare Symposium on November 19, 2020. The focus will be on their lead drug candidate, seclidemstat, an oral medication targeting lysine-specific demethylase 1 (LSD1), crucial in some cancers. Ongoing Phase 1/2 trials for seclidemstat involve patients with refractory Ewing sarcoma and advanced solid tumors. Notably, one patient showed over 80% reduction in target lesions after six months of treatment.
Salarius Pharmaceuticals (Nasdaq: SLRX) reported its Q3 2020 financial results, revealing a net loss of $1.7 million, or $0.10 per share, significantly reduced from a loss of $2.6 million or $0.73 per share year-over-year. The company’s cash position improved to $9.6 million, aided by a $6.2 million public offering in August 2020. The Ewing sarcoma clinical trial is progressing, with plans to enter the Phase 2 dose-expansion stage in Q1 2021 and an expansion to include Ewing-related sarcomas. Salarius aims to leverage these developments for future growth.
Salarius Pharmaceuticals (SLRX) announced a conference call on November 11, 2020, at 4:30 p.m. ET to discuss its third-quarter 2020 corporate and financial results. Investors can join the call by dialing (833) 423-0481 or (918) 922-2375 with Conference ID 1277839. An audio webcast will also be available on the company's website. Salarius focuses on developing cancer therapies, including its lead candidate, seclidemstat, which is in clinical trials for pediatric and other cancers and has received multiple designations from the FDA.
Salarius Pharmaceuticals announced that CEO David Arthur will present at the BIO Investor Forum Digital from October 13 to 15, 2020. The presentation, available on demand, will cover the company's business overview, recent achievements, and milestones for their lead candidate seclidemstat. This reversible LSD1 inhibitor is currently in Phase 1/2 trials for Ewing sarcoma, a rare pediatric cancer, and advanced solid tumors. The presentation will also include details on Salarius' regulatory designations and ongoing clinical programs.
Salarius Pharmaceuticals (Nasdaq: SLRX) has announced participation in two investor conferences in September 2020. CEO David Arthur will present the company's business model, recent achievements, and upcoming milestones, particularly highlighting seclidemstat, their leading drug candidate in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. The presentations are scheduled for September 16 and 17, 2020, with live webcasts available. Salarius, focusing on oncological treatments, has received Fast Track and Orphan Drug Designations from the FDA, showcasing its commitment to addressing critical cancer needs.
Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX) announced that CEO David Arthur will present at the 2020 LD 500 Conference, taking place virtually from September 1-4, 2020. Arthur's presentation will cover Salarius' business overview and recent clinical achievements, particularly for its lead compound, seclidemstat, a reversible LSD1 inhibitor currently in Phase 1/2 trials for Ewing sarcoma and advanced solid tumors. The presentation is scheduled for September 1 at 3:20 PM ET, with a live webcast available for attendees.
FAQ
What is the current stock price of Salarius Pharmaceuticals (SLRX)?
What is the market cap of Salarius Pharmaceuticals (SLRX)?
